Stocktoria
HYPERION DEFI, INC. HYPD
HYPERION DEFI, INC. (HYPD) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $813,455 at a -5570.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.088 |
| Retained earnings / assets | -4.648 |
| EBIT / assets | -0.903 |
| Equity / liabilities | 3.836 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| HYPD | HYPERION DEFI, INC. | 5/9 | -16.62 | — | — |
| ONCO | Onconetix, Inc. | 4/9 | — | — | — |
| MCRB | Seres Therapeutics, Inc. | 5/9 | — | 12 | — |
| RLYB | Rallybio Corp | 3/9 | 0.76 | — | — |
| BGMS | Bio Green Med Solution, Inc. | 3/9 | — | — | — |
| RFL | Rafael Holdings, Inc. | 3/9 | 0.8 | — | — |
| LEXX | Lexaria Bioscience Corp. | 4/9 | — | — | — |
About HYPERION DEFI, INC.
Hyperion DeFi, Inc., a DeFi company, engages in building on Hyperliquid. It operates through two segments: Ophthalmic Technology and Digital Assets. The company focuses on the long-term strategic treasury of HYPE tokens to provide simplified exposure to the Hyperliquid blockchain ecosystem. It is also developing the Optejet User Filled Device to work with various topical ophthalmic liquids, including artificial tears and lens rewetting products. The company was formerly known as Eyenovia, Inc. and changed its name to Hyperion DeFi, Inc. in July 2025. Hyperion DeFi, Inc. was founded in 2014 and is based in Dallas, Texas.
FAQ
Is HYPD financially healthy?
HYPERION DEFI, INC.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does HYPD pay a dividend?
No, HYPERION DEFI, INC. does not currently pay a dividend.
How profitable is HYPD?
In FY2025, HYPERION DEFI, INC. had a net margin of -5570.6% and a return on equity of -110.4%.
What is the analyst price target for HYPD?
The average Wall-Street price target for HYPERION DEFI, INC. is $5.65, about 110.0% above the recent price, from 2 analysts.
Is HYPD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on HYPERION DEFI, INC.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.